Should I buy or sell OrthoPediatrics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OrthoPediatrics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KIDS shares. View KIDS analyst ratings or view top-rated stocks .

What is OrthoPediatrics' stock price target for 2024?

4 Wall Street analysts have issued 12 month target prices for OrthoPediatrics' shares. Their KIDS share price targets range from $31.00 to $52.00. On average, they anticipate the company's stock price to reach $42.50 in the next twelve months. This suggests a possible upside of 44.3% from the stock's current price. View analysts price targets for KIDS or view top-rated stocks among Wall Street analysts .

How have KIDS shares performed in 2024?

OrthoPediatrics' stock was trading at $32.51 on January 1st, 2024. Since then, KIDS stock has decreased by 9.4% and is now trading at $29.46. View the best growth stocks for 2024 here .

Are investors shorting OrthoPediatrics?

OrthoPediatrics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,040,000 shares, an increase of 10.5% from the March 15th total of 941,200 shares. Based on an average trading volume of 179,900 shares, the short-interest ratio is currently 5.8 days. Approximately 6.6% of the company's stock are sold short. View OrthoPediatrics' Short Interest .

When is OrthoPediatrics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our KIDS earnings forecast .

How were OrthoPediatrics' earnings last quarter?

OrthoPediatrics Corp. (NASDAQ:KIDS) announced its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.05. The firm earned $37.61 million during the quarter, compared to analysts' expectations of $37.59 million. OrthoPediatrics had a negative net margin of 14.10% and a negative trailing twelve-month return on equity of 5.03%.

What guidance has OrthoPediatrics issued on next quarter's earnings?

OrthoPediatrics issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $197.0 million-$200.0 million, compared to the consensus revenue estimate of $182.9 million.

What is Mark Throdahl's approval rating as OrthoPediatrics' CEO?

15 employees have rated OrthoPediatrics Chief Executive Officer Mark Throdahl on Glassdoor.com . Mark Throdahl has an approval rating of 100% among the company's employees. This puts Mark Throdahl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OrthoPediatrics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrthoPediatrics investors own include AbbVie (ABBV) , Freeport-McMoRan (FCX) , Gilead Sciences (GILD) , Intel (INTC) , Advanced Micro Devices (AMD) , CRISPR Therapeutics (CRSP) , Cisco Systems (CSCO) , Walt Disney (DIS) , Enterprise Products Partners (EPD) and NVIDIA (NVDA) .

When did OrthoPediatrics IPO?

OrthoPediatrics (KIDS) raised $52 million in an initial public offering on Thursday, October 12th 2017. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Piper and Jaffray Stifel acted as the underwriters for the IPO and William Blair and BTIG were co-managers.

How do I buy shares of OrthoPediatrics?

Shares of KIDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KIDS

OrthoPediatrics (KIDS) Stock Price, News & Analysis

→ Special FREE offer on stock hotsheets (From DTI) (Ad)

Free KIDS Stock Alerts

$29.46

-0.44 (-1.47%)

(As of 04/18/2024 ET)

Compare

Today's Range: $29.46
▼
$30.42
50-Day Range: $24.99
▼
$31.77
52-Week Range: $23.10
▼
$53.50

Volume: 81,159 shs
Average Volume: 186,183 shs
Market Capitalization: $700.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $42.50

Get OrthoPediatrics alerts:

OrthoPediatrics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 44.3% Upside
$42.50 Price Target
Short Interest: Bearish
6.55% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.20
Upright™ Environmental Score
News Sentiment: 0.39
Based on 2 Articles This Week
Insider Trading: Selling Shares
$477,375 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.34) to ($1.32) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.88 out of 5 stars

Medical Sector

190th out of 918 stocks

Surgical & Medical Instruments Industry

26th out of 92 stocks

3.4

Analyst's Opinion

Consensus Rating
OrthoPediatrics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
OrthoPediatrics has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.55% of the float of OrthoPediatrics has been sold short.
Short Interest Ratio / Days to Cover
OrthoPediatrics has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in OrthoPediatrics has recently increased by 10.50%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
OrthoPediatrics does not currently pay a dividend.
Dividend Growth
OrthoPediatrics does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
OrthoPediatrics has received a 52.35% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic bone grafts", "Cervical implants", and "Medical screws" products. See details.
Environmental Sustainability
The Environmental Impact score for OrthoPediatrics is -1.20.

1.9

News and Social Media Coverage

News Sentiment
OrthoPediatrics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for OrthoPediatrics this week, compared to 2 articles on an average week.
MarketBeat Follows
3 people have added OrthoPediatrics to their MarketBeat watchlist in the last 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OrthoPediatrics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $477,375.00 in company stock.
Percentage Held by Insiders
32.60% of the stock of OrthoPediatrics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
69.05% of the stock of OrthoPediatrics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for OrthoPediatrics are expected to grow in the coming year, from ($1.34) to ($1.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OrthoPediatrics is -32.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OrthoPediatrics is -32.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
OrthoPediatrics has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Start loving Mondays like this

Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!

Weekend after weekend!

About OrthoPediatrics Stock (NASDAQ:KIDS)

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

KIDS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KIDS Stock News Headlines

April 16, 2024 | americanbankingnews.com

OrthoPediatrics Corp. (NASDAQ:KIDS) Short Interest Up 10.5% in March

April 11, 2024 | americanbankingnews.com

OrthoPediatrics (NASDAQ:KIDS) Rating Reiterated by Needham & Company LLC

April 18, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.

April 10, 2024 | markets.businessinsider.com

The Analyst Verdict: OrthoPediatrics In The Eyes Of 6 Experts

April 4, 2024 | finance.yahoo.com

OrthoPediatrics Corp. to Highlight its Pediatric Scoliosis Solutions at 8th Annual International Children’s Spine Symposium (ICSS)

April 4, 2024 | globenewswire.com

OrthoPediatrics Corp. to Highlight its Pediatric Scoliosis Solutions at 8th Annual International Children's Spine Symposium (ICSS)

March 26, 2024 | globenewswire.com

OrthoPediatrics Corp. to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 18, 2024 | markets.businessinsider.com

Two Pediatric Medical Device Companies Receive Prestigious Award at MedTech Color Edition of Make Your Medical Device Pitch For Kids!™ Competition

April 18, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

March 15, 2024 | finance.yahoo.com

KIDS Apr 2024 40.000 put

March 13, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), OrthoPediatrics (KIDS) and RegenXBio (RGNX)

March 7, 2024 | realmoney.thestreet.com

OrthoPediatrics price target raised by $2 at Stifel, here's why

March 7, 2024 | markets.businessinsider.com

Cracking The Code: Understanding Analyst Reviews For OrthoPediatrics

March 7, 2024 | finance.yahoo.com

OrthoPediatrics Corp (KIDS) Reports Robust Revenue Growth and Improved Adjusted EBITDA in 2023

March 6, 2024 | msn.com

KIDS Stock Earnings: OrthoPediatrics Beats EPS, Misses Revenue for Q4 2023

March 6, 2024 | washingtonpost.com

OrthoPediatrics: Q4 Earnings Snapshot

March 6, 2024 | benzinga.com

Recap: OrthoPediatrics Q4 Earnings

March 6, 2024 | globenewswire.com

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results

March 4, 2024 | globenewswire.com

OrthoPediatrics Corp. Launches New RESPONSE Rib and Pelvic Fixation System for EOS Scoliosis

February 28, 2024 | globenewswire.com

OrthoPediatrics Corp. Named One of the 2024 Best Places to Work in Indiana

February 22, 2024 | globenewswire.com

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

February 20, 2024 | finance.yahoo.com

OrthoPediatrics (KIDS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

February 19, 2024 | cnet.com

Best Mattresses for Kids in 2024

January 31, 2024 | finance.yahoo.com

Calling all MedTech innovators: Up to $100,000 in federal grants to be awarded

January 25, 2024 | realmoney.thestreet.com

OrthoPediatrics just downgraded at Truist, here's why

January 25, 2024 | markets.businessinsider.com

Decoding 5 Analyst Evaluations For OrthoPediatrics

January 15, 2024 | benzinga.com

OrthoPediatrics Stock (NASDAQ:KIDS) Dividends: History, Yield and Dates

See More Headlines

Receive KIDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OrthoPediatrics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/06/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:KIDS
CUSIP: N/A
CIK: 1425450
Web: www.orthopediatrics.com
Phone: (574) 268-6379
Fax: 574-269-3692
Employees: 247
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $42.50
High Stock Price Target: $52.00
Low Stock Price Target: $31.00
Potential Upside/Downside: +43.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,970,000.00
Net Margins: -14.10%
Pretax Margin: -14.33%
Return on Equity: -5.03%
Return on Assets: -4.37%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 5.44
Quick Ratio: 2.90

Sales & Book Value

Annual Sales: $148.73 million
Price / Sales: 4.74
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $16.14 per share
Price / Book: 1.84

Miscellaneous

Outstanding Shares: 23,790,000
Free Float: 16,032,000
Market Cap: $705.14 million
Optionable: Optionable
Beta: 1.16

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Mark C. Throdahl (Age 73)
Executive Chairman
Mr. David R. Bailey (Age 45)
President, CEO & Director
Comp: $588.47k
Mr. Fred L. Hite (Age 56)
CFO, Principal Financial & Accounting Officer, COO and Director
Comp: $578.75k
Mr. Daniel J. Gerritzen (Age 54)
Executive VP of Legal & General Counsel
Comp: $470.44k
Mr. Gregory A. Odle (Age 54)
President of Scoliosis
Comp: $484.32k
Mr. Kevin L. Unger CHE (Age 52)
MBA/MSHA, President of Enabling Technologies
Comp: $56.25k
Mr. Joseph W. Hauser (Age 42)
President of Trauma & Deformity Correction
Comp: $470.44k
Mr. Joel Batts
Senior Vice President of Clinical & Regulatory Affairs
Mr. Mark Karshner
Senior Vice President of International Sales

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KIDS Stock Analysis - Frequently Asked Questions

Should I buy or sell OrthoPediatrics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OrthoPediatrics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KIDS shares.
View KIDS analyst ratings or view top-rated stocks.
What is OrthoPediatrics' stock price target for 2024?: 4 Wall Street analysts have issued 12 month target prices for OrthoPediatrics' shares. Their KIDS share price targets range from $31.00 to $52.00. On average, they anticipate the company's stock price to reach $42.50 in the next twelve months. This suggests a possible upside of 44.3% from the stock's current price.
View analysts price targets for KIDS or view top-rated stocks among Wall Street analysts.
How have KIDS shares performed in 2024?: OrthoPediatrics' stock was trading at $32.51 on January 1st, 2024. Since then, KIDS stock has decreased by 9.4% and is now trading at $29.46.
View the best growth stocks for 2024 here.
Are investors shorting OrthoPediatrics?: OrthoPediatrics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,040,000 shares, an increase of 10.5% from the March 15th total of 941,200 shares. Based on an average trading volume of 179,900 shares, the short-interest ratio is currently 5.8 days. Approximately 6.6% of the company's stock are sold short.
View OrthoPediatrics' Short Interest.
When is OrthoPediatrics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our KIDS earnings forecast.
How were OrthoPediatrics' earnings last quarter?: OrthoPediatrics Corp. (NASDAQ:KIDS) announced its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.05. The firm earned $37.61 million during the quarter, compared to analysts' expectations of $37.59 million. OrthoPediatrics had a negative net margin of 14.10% and a negative trailing twelve-month return on equity of 5.03%.

What guidance has OrthoPediatrics issued on next quarter's earnings?: OrthoPediatrics issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $197.0 million-$200.0 million, compared to the consensus revenue estimate of $182.9 million.
What is Mark Throdahl's approval rating as OrthoPediatrics' CEO?: 15 employees have rated OrthoPediatrics Chief Executive Officer Mark Throdahl on Glassdoor.com. Mark Throdahl has an approval rating of 100% among the company's employees. This puts Mark Throdahl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of OrthoPediatrics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OrthoPediatrics investors own include AbbVie (ABBV), Freeport-McMoRan (FCX), Gilead Sciences (GILD), Intel (INTC), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Cisco Systems (CSCO), Walt Disney (DIS), Enterprise Products Partners (EPD) and NVIDIA (NVDA).
When did OrthoPediatrics IPO?: OrthoPediatrics (KIDS) raised $52 million in an initial public offering on Thursday, October 12th 2017. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Piper and Jaffray Stifel acted as the underwriters for the IPO and William Blair and BTIG were co-managers.
How do I buy shares of OrthoPediatrics?: Shares of KIDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KIDS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial